Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RBOT 
Vicarious Surgical Inc. (RBOT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: RBOT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.25% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.81M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 3 | Beta 1.39 | 52 Weeks Range 5.00 - 19.00 | Updated Date 10/17/2025 |
52 Weeks Range 5.00 - 19.00 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.07 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.73% | Return on Equity (TTM) -125.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22269948 | Price to Sales(TTM) - |
Enterprise Value 22269948 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.41 | Shares Outstanding 5894024 | Shares Floating 3126416 |
Shares Outstanding 5894024 | Shares Floating 3126416 | ||
Percent Insiders 20.34 | Percent Institutions 30.33 |
Upturn AI SWOT
Vicarious Surgical Inc.
Company Overview
History and Background
Vicarious Surgical Inc. was founded in 2014. It focuses on developing miniaturized surgical robots that can access and treat areas in the body that are difficult to reach using traditional surgical methods. The company went public via SPAC merger in 2021.
Core Business Areas
- Surgical Robotics: Development and manufacturing of a surgical robot designed for minimally invasive procedures, offering enhanced visualization and dexterity compared to traditional laparoscopic surgery.
Leadership and Structure
Adam Sachs is the CEO. The company has a board of directors and is organized into functional departments such as R&D, engineering, regulatory affairs, and operations.
Top Products and Market Share
Key Offerings
- Vicarious Surgical Robot: The primary product is a surgical robot featuring human-like arms and a high-definition 3D visualization system designed to enhance surgical precision and accessibility. The product is still pre-revenue and has no considerable market share at this time as it awaits regulatory approval. Key competitors in the overall surgical robotics space include Intuitive Surgical (ISRG), Stryker (SYK), and Medtronic (MDT).
Market Dynamics
Industry Overview
The surgical robotics industry is experiencing significant growth, driven by the increasing demand for minimally invasive procedures, advancements in robotics technology, and an aging population. Regulatory hurdles and high capital costs remain challenges.
Positioning
Vicarious Surgical is positioned as an innovator in surgical robotics, focusing on miniaturization and enhanced dexterity. Its key competitive advantage lies in its unique technology that enables access to previously unreachable anatomical locations.
Total Addressable Market (TAM)
The TAM for surgical robotics is projected to reach billions of dollars. Vicarious Surgical aims to capture a significant share of this market by focusing on complex procedures in high-growth areas. TAM is estimated to be around $40 Billion.
Upturn SWOT Analysis
Strengths
- Innovative miniaturized robotics technology
- Potential for improved surgical outcomes
- Strong intellectual property portfolio
- Experienced leadership team
Weaknesses
- Pre-revenue stage
- Reliance on regulatory approvals
- High capital requirements
- Limited clinical data
Opportunities
- Expanding applications to new surgical specialties
- Partnerships with leading hospitals and surgeons
- Geographic expansion
- Potential for licensing technology
Threats
- Competition from established players
- Technological obsolescence
- Regulatory hurdles
- Economic downturn affecting hospital spending
Competitors and Market Share
Key Competitors
- ISRG
- SYK
- MDT
Competitive Landscape
Vicarious Surgical faces intense competition from established players with significant resources and existing market presence. Its competitive advantage lies in its differentiated technology, but it needs to overcome regulatory hurdles and build a strong commercialization strategy.
Growth Trajectory and Initiatives
Historical Growth: N/A (Pre-revenue)
Future Projections: Future growth is dependent on regulatory approvals and successful commercialization of its surgical robot. Analyst estimates vary widely depending on the timeline for product launch.
Recent Initiatives: Recent initiatives include progressing through regulatory approval processes with the FDA, presenting clinical data, and securing additional funding.
Summary
Vicarious Surgical is a high-risk, high-reward company in the early stages of commercialization. Its innovative technology holds significant promise, but its success depends on regulatory approval, successful product launch, and effective competition against established players. Current lack of revenue makes it speculative.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, industry publications, company website
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Future performance is subject to various risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vicarious Surgical Inc.
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 2020-09-04 | CEO & Director Mr. Stephen From | ||
Sector Healthcare | Industry Medical Devices | Full time employees 121 | |
Full time employees 121 | |||
Vicarious Surgical Inc. develops and sells single-port surgical robot in the United States. It offers Vicarious Surgical System, a single-port surgical robot that virtually transports surgeons inside the patient to perform invasive surgery. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.